MiR-135a inhibits non-small cell lung cancer progression by suppressing RAB1B expression and the RAS pathway

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung cancer remains a leading cause of cancer-related mortality globally and in China.
• Noncoding RNAs, particularly microRNAs, play crucial roles in cancer development and progression.
• Aberrant microRNA expression is increasingly recognized as a hallmark of various cancers, including non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To investigate the role of miR-135a in non-small cell lung cancer (NSCLC).
• To identify novel targets and regulatory mechanisms of miR-135a in lung cancer.
• To evaluate the potential of miR-135a as a prognostic biomarker and therapeutic target for NSCLC.

Main Methods:

• Quantitative real-time PCR to assess miR-135a expression in NSCLC tissues and cell lines.
• In vitro assays (proliferation, invasion, migration) to evaluate the functional role of miR-135a.
• Western blotting and luciferase reporter assays to identify and validate direct targets of miR-135a, including RAB1B and RAS pathway components.

Main Results:

• miR-135a was significantly downregulated in NSCLC cells compared to normal bronchial epithelial cells.
• Restoration of miR-135a expression suppressed NSCLC cell proliferation, invasion, and metastasis in vitro.
• miR-135a directly targets RAB1B, leading to the inhibition of multiple RAS pathway components (RAS, Raf1, Rac1, RhoA).
• Expression levels of miR-135a and its novel target RAB1B correlated with clinical outcomes in NSCLC patients.

Conclusions:

• miR-135a functions as a tumor suppressor in NSCLC by inhibiting proliferation, invasion, and metastasis.
• The miR-135a/RAB1B axis represents a novel regulatory pathway in NSCLC.
• miR-135a and RAB1B hold promise as predictive biomarkers for clinical outcomes and potential therapeutic targets for NSCLC.